Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 66, Issue 2, Pages 235-239Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkq448
Keywords
antituberculosis; anticoagulants; pulmonary hypertension; chemotherapy; HIV
Funding
- Abbott Laboratories
Ask authors/readers for more resources
With HIV-infected patients living longer and recommendations to initiate antiretrovirals (ARVs) being made earlier, the likelihood for potential drug-drug interactions between ARVs and concurrent medications used to manage co-morbid conditions will increase. In order to maximize the clinical benefit and minimize potential toxicity of ARVs and co-administered medications, it is important for clinicians to recognize significant drug-drug interactions. This article highlights clinically significant drug-drug interactions with antituberculosis agents, antimalarials, anticoagulants, chemotherapeutic agents and pulmonary antihypertensive agents when they are co-administered with newer ARVs (e.g. darunavir, raltegravir, maraviroc and etravirine).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available